Atrium Biotechnologies collaborates with IEB for peptides range

Developed by IEB at its laboratories in France, the biomimetic peptides have been developed for skin care formulations that aim to provide anti-aging, photo damage, suncare, tissue repair, skin whitening and soothing properties for a range of skin care products.

Atriium Biotechnologies says that with this move, combined with future plans to further develop its peptides portfolio, it is now aiming to become a recognized major player in the international peptides field.

The first of the five peptides is ECM-Protect, that has been developed to bring about firmness and elasticity for skin. According to the manufacturers, this is achieved through limiting the enzymatic activity of the collagen and elastin in skin, in turn helping to fight signs of aging.

Kollaren has been developed as a dermis enhancer. It is said to increase the firmness of the skin by activating the extacellular matrix proteins of the skin structure. Its reparation properties in turn encourage tissue renewal and help to restore the biomechanical properties of the skin, it is claimed.

Melanostatine is a peptide that has been developed for skin whitening, and is likely to be most popular on the Asian market. It has been developed to compete against natural ligand, by preventing the activation of tyrosinase, which thus blocks the melanin synthesis that leads to darker skin, freckles and sun spots.

A healthy glow is the aim of Melitane, a peptide that has been developed to regulate a-MSH, which in turn regulates melanin synthesis. The stimulation of melanin in turn strengthens the skin's defense against harmful effects of UV and reduces potential inflammation, making it a good bet for both moisturizer and sun care formulations.

Focusing on anti-aging, Thymulen 4 is derived from the youth hormone thympoieten and in turn aims to regulate the natural loss of thymic factors associated with skin aging. It is said to increase immuno-vigilence of the skin and, which also regulates the epidermal profile.

Atrium Biotechnologies​ says that the peptides will be launched in France, the United States, Germany and Korea.

The rise in the popularity of peptides in cosmetics formulations is being driven by demand for efficient actives that deliver a range of functions to skin care and other cosmetics preparations.

The fact that they are considered to be stable, safe and chemically well-defined also makes them appealing to formulators.